{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T18:45:07Z","timestamp":1786128307126,"version":"build-2736575974"},"reference-count":79,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T00:00:00Z","timestamp":1784592000000},"content-version":"vor","delay-in-days":201,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"HMZ Flagship Grant"},{"name":"the Clinical Research Priority Program (CRPP) of the University of Zurich for the CRPP ImmunoCure"},{"name":"the Swiss National Science Foundation","award":["SNF 320030_219458"],"award-info":[{"award-number":["SNF 320030_219458"]}]},{"name":"the Swiss National Science Foundation","award":["SNF 310030_ 212358"],"award-info":[{"award-number":["SNF 310030_ 212358"]}]},{"name":"the Eurostars-3 programme","award":["#765"],"award-info":[{"award-number":["#765"]}]},{"DOI":"10.13039\/501100004543","name":"China Scholarship Council","doi-asserted-by":"publisher","award":["202106100136"],"award-info":[{"award-number":["202106100136"]}],"id":[{"id":"10.13039\/501100004543","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Swiss Cancer League project","award":["KLS-4870-08-2019"],"award-info":[{"award-number":["KLS-4870-08-2019"]}]},{"name":"Swiss Cancer League project","award":["KFS-6103-02-2024"],"award-info":[{"award-number":["KFS-6103-02-2024"]}]},{"name":"Swiss Cancer League project","award":["KFS-5533-02-2022"],"award-info":[{"award-number":["KFS-5533-02-2022"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>A significant proportion of meningiomas are resistant to current treatments. Somatostatin receptor 2 (SSTR2) is highly and consistently expressed in most meningiomas, providing a promising target for localized chimeric antigen receptor (CAR)-T cell therapy. Short-lived small-molecule CAR adapters can potentially prevent CAR-T cell exhaustion in solid tumors by alternating between active and resting states.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We developed the CAR adapter peptide Octofluo, which combines fluorescein-5-isothiocyanate (FITC) with a high-avidity SSTR2 antagonist. After determining its biodistribution, killing efficiency of CAR-T cells plus Octofluo against human meningioma was evaluated in vitro and ex vivo. Therapeutic capacity was assessed in vivo against xenograft and syngeneic genetically engineered mouse meningioma models.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We herein demonstrate rapid tissue diffusion and transient tumor persistence for only a few hours after intravenous administration of Octofluo, making a suitable switch for on-demand CAR-T cell activation. Nanomolar concentrations of Octofluo effectively directed FITC-specific CAR-T cells against SSTR2-expressing meningioma cells. Combined intratumoral CAR-T cell delivery and intravenous octofluo infusion at periodic intervals showed limited efficacy in an immunocompromised xenograft model but cured most mice with an intact immune system harboring highly aggressive, genetically induced higher grade meningiomas. Cures were accompanied by CAR-T cell expansion and an endogenous T cell response, suggesting a role for the host immune system in tumor elimination. Ex vivo lysis of patient-derived meningioma cells was observed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The combination of systemic octofluo administration and locally applied CAR-T cells is a promising strategy for future clinical development for patients with refractory meningiomas.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/noajnl\/vdag186","type":"journal-article","created":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T11:28:10Z","timestamp":1784633290000},"source":"Crossref","is-referenced-by-count":0,"title":["A fluorescein-conjugated somatostatin receptor antagonist adapter for chimeric antigen receptor T cell therapy of meningioma"],"prefix":"10.1093","volume":"8","author":[{"given":"Jiawei","family":"Chen","sequence":"first","affiliation":[{"name":"Department of Neurology, University Hospital and University of Zurich , Zurich,","place":["Switzerland"]},{"name":"Department of Neurosurgery, Huashan Hospital, Shanghai Medical College, Fudan University , Shanghai,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Pellegrino","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology and Hematology, University Hospital and University of Zurich , Zurich,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0571-9423","authenticated-orcid":false,"given":"Maximilian","family":"Mastall","sequence":"additional","affiliation":[{"name":"Department of Neurology, University Hospital and University of Zurich , Zurich,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Szulzewsky","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Clinical Neurosciences Center, University of Utah , Salt Lake City, Utah,","place":["USA"]},{"name":"Huntsman Cancer Institute, University of Utah Health Sciences Center , Salt Lake City, Utah,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitchell","family":"Bijnen","sequence":"additional","affiliation":[{"name":"Institute of Experimental Immunology, University of Zurich , Zurich,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah J","family":"Van Hove","sequence":"additional","affiliation":[{"name":"Institute of Experimental Immunology, University of Zurich , Zurich,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Favalli","sequence":"additional","affiliation":[{"name":"Philochem AG , Otelfingen,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriele","family":"Bassi","sequence":"additional","affiliation":[{"name":"Philochem AG , Otelfingen,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vlad","family":"Moisoiu","sequence":"additional","affiliation":[{"name":"Department of Neurology, University Hospital and University of Zurich , Zurich,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8953-0862","authenticated-orcid":false,"given":"Flavio","family":"Vasella","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Clinical Neuroscience Center, University Hospital and University of Zurich , Zurich,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"Padevit","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Clinical Neuroscience Center, University Hospital and University of Zurich , Zurich,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marian C","family":"Neidert","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Cantonal Hospital St. Gallen , St.Gallen,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allison","family":"Shelbourn","sequence":"additional","affiliation":[{"name":"Neuropathology Unit, Surgical Neurology Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health , Bethesda, Maryland,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0441-4502","authenticated-orcid":false,"given":"Patrick J","family":"Cimino","sequence":"additional","affiliation":[{"name":"Molecular Neuropathology, Department of Pathology and Laboratory Medicine, Children\u2019s National Research Institute and George Washington University School of Medicine and Health Sciences, Washington, District of Columbia ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6396-4195","authenticated-orcid":false,"given":"Regina","family":"Reimann","sequence":"additional","affiliation":[{"name":"Institute of Neuropathology, University Hospital and University of Zurich , Zurich,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3897-214X","authenticated-orcid":false,"given":"Patrick","family":"Roth","sequence":"additional","affiliation":[{"name":"Department of Neurology, University Hospital and University of Zurich , Zurich,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus G","family":"Manz","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology and Hematology, University Hospital and University of Zurich , Zurich,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7220-5369","authenticated-orcid":false,"given":"Melanie","family":"Greter","sequence":"additional","affiliation":[{"name":"Institute of Experimental Immunology, University of Zurich , Zurich,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric C","family":"Holland","sequence":"additional","affiliation":[{"name":"Human Biology Division, Fred Hutchinson Cancer Center , Seattle, Washington,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dario","family":"Neri","sequence":"additional","affiliation":[{"name":"Philochem AG , Otelfingen,","place":["Switzerland"]},{"name":"Department of Chemistry and Applied Biosciences, Federal Institute of Technology (ETH) , Zurich,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1748-174X","authenticated-orcid":false,"given":"Michael","family":"Weller","sequence":"additional","affiliation":[{"name":"Department of Neurology, University Hospital and University of Zurich , Zurich,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6254-4204","authenticated-orcid":false,"given":"Hans-Georg","family":"Wirsching","sequence":"additional","affiliation":[{"name":"Department of Neurology, University Hospital and University of Zurich , Zurich,","place":["Switzerland"]},{"name":"Department of Neurology, Cantonal Hospital Winterthur , Zurich,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,7,21]]},"reference":[{"key":"2026080714063678000_vdag186-B1","doi-asserted-by":"publisher","first-page":"1700","DOI":"10.1038\/s41591-023-02415-3","article-title":"Transcriptional signatures associated with persisting CD19 CAR-T cells in children with leukemia","volume":"29","author":"Anderson","year":"2023","journal-title":"Nat Med."},{"key":"2026080714063678000_vdag186-B2","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1016\/S1470-2045(23)00246-2","article-title":"Gamma-secretase inhibitor in combination with BCMA chimeric antigen receptor T-cell immunotherapy for individuals with relapsed or refractory multiple myeloma: a phase 1, first-in-human trial","volume":"24","author":"Cowan","year":"2023","journal-title":"Lancet Oncol."},{"key":"2026080714063678000_vdag186-B3","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1038\/s41571-019-0297-y","article-title":"Engineering strategies to overcome the current roadblocks in CAR T cell therapy","volume":"17","author":"Rafiq","year":"2020","journal-title":"Nat Rev Clin Oncol."},{"key":"2026080714063678000_vdag186-B4","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant."},{"key":"2026080714063678000_vdag186-B5","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1158\/2159-8290.CD-17-1319","article-title":"Clinical and biological correlates of neurotoxicity associated with CAR T-cell therapy in patients with B-cell acute lymphoblastic leukemia","volume":"8","author":"Santomasso","year":"2018","journal-title":"Cancer Discov."},{"key":"2026080714063678000_vdag186-B6","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/s41577-021-00547-6","article-title":"Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy","volume":"22","author":"Morris","year":"2022","journal-title":"Nat Rev Immunol."},{"key":"2026080714063678000_vdag186-B7","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1038\/s41591-023-02276-w","article-title":"Tumor inflammation-associated neurotoxicity","volume":"29","author":"Mahdi","year":"2023","journal-title":"Nat Med."},{"key":"2026080714063678000_vdag186-B8","doi-asserted-by":"publisher","DOI":"10.1126\/science.aba1786","article-title":"Transient rest restores functionality in exhausted CAR-T cells through epigenetic remodeling","volume":"372","author":"Weber","year":"2021","journal-title":"Science."},{"key":"2026080714063678000_vdag186-B9","doi-asserted-by":"publisher","first-page":"1113882","DOI":"10.3389\/fimmu.2023.1113882","article-title":"The current landscape of CAR T-cell therapy for solid tumors: Mechanisms, research progress, challenges, and counterstrategies","volume":"14","author":"Daei Sorkhabi","year":"2023","journal-title":"Front Immunol."},{"key":"2026080714063678000_vdag186-B10","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/s41571-023-00832-4","article-title":"CAR T cell therapy for patients with solid tumours: key lessons to learn and unlearn","volume":"21","author":"Albelda","year":"2024","journal-title":"Nat Rev Clin Oncol."},{"key":"2026080714063678000_vdag186-B11","doi-asserted-by":"publisher","first-page":"E450","DOI":"10.1073\/pnas.1524193113","article-title":"Versatile strategy for controlling the specificity and activity of engineered T cells","volume":"113","author":"Ma","year":"2016","journal-title":"Proc Natl Acad Sci U S A."},{"key":"2026080714063678000_vdag186-B12","doi-asserted-by":"publisher","first-page":"1426","DOI":"10.1016\/j.cell.2018.03.038","article-title":"Universal chimeric antigen receptors for multiplexed and logical control of T cell responses","volume":"173","author":"Cho","year":"2018","journal-title":"Cell."},{"key":"2026080714063678000_vdag186-B13","doi-asserted-by":"publisher","first-page":"1775","DOI":"10.1021\/acs.bioconjchem.0c00258","article-title":"Impact of ligand size and conjugation chemistry on the performance of universal chimeric antigen receptor T-Cells for tumor killing","volume":"31","author":"Pellegrino","year":"2020","journal-title":"Bioconjug Chem."},{"key":"2026080714063678000_vdag186-B14","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1158\/0008-5472.CAN-18-1834","article-title":"Use of a single CAR T cell and several bispecific adapters facilitates eradication of multiple antigenically different solid tumors","volume":"79","author":"Lee","year":"2019","journal-title":"Cancer Res."},{"key":"2026080714063678000_vdag186-B15","doi-asserted-by":"publisher","first-page":"115286","DOI":"10.1016\/j.ejmech.2023.115286","article-title":"Discovery of a spirocyclic 3-bromo-4,5-dihydroisoxazole covalent inhibitor of hGAPDH with antiproliferative activity against pancreatic cancer cells","volume":"254","author":"Galbiati","year":"2023","journal-title":"Eur J Med Chem."},{"key":"2026080714063678000_vdag186-B16","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1021\/acs.bioconjchem.3c00244","article-title":"A comparative analysis of fibroblast activation protein-targeted small molecule-drug, antibody-drug, and peptide-drug conjugates","volume":"34","author":"Zana","year":"2023","journal-title":"Bioconjug Chem."},{"key":"2026080714063678000_vdag186-B17","doi-asserted-by":"publisher","first-page":"3656","DOI":"10.1158\/1078-0432.CCR-17-3457","article-title":"Enhanced therapeutic activity of non-internalizing small-molecule-drug conjugates targeting carbonic anhydrase IX in combination with targeted interleukin-2","volume":"24","author":"Cazzamalli","year":"2018","journal-title":"Clin Cancer Res."},{"key":"2026080714063678000_vdag186-B18","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","article-title":"The 2021 WHO classification of tumors of the central nervous system: a summary","volume":"23","author":"Louis","year":"2021","journal-title":"Neuro Oncol."},{"key":"2026080714063678000_vdag186-B19","doi-asserted-by":"publisher","first-page":"iv1","DOI":"10.1093\/neuonc\/noad149","article-title":"CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2016-2020","volume":"25","author":"Ostrom","year":"2023","journal-title":"Neuro Oncol."},{"key":"2026080714063678000_vdag186-B20","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1007\/s10143-018-0976-7","article-title":"Meningiomas: skull base versus non-skull base","volume":"42","author":"Meling","year":"2019","journal-title":"Neurosurg Rev."},{"key":"2026080714063678000_vdag186-B21","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/978-3-031-29750-2_2","article-title":"Clinical presentation and prognosis","volume":"1416","author":"Millward","year":"2023","journal-title":"Adv Exp Med Biol."},{"key":"2026080714063678000_vdag186-B22","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1038\/s41586-021-03850-3","article-title":"A clinically applicable integrative molecular classification of meningiomas","volume":"597","author":"Nassiri","year":"2021","journal-title":"Nature."},{"key":"2026080714063678000_vdag186-B23","doi-asserted-by":"publisher","first-page":"3839","DOI":"10.1200\/JCO.21.00784","article-title":"integrated molecular-morphologic meningioma classification: a multicenter retrospective analysis, retrospectively and prospectively validated","volume":"39","author":"Maas","year":"2021","journal-title":"J Clin Oncol"},{"key":"2026080714063678000_vdag186-B24","doi-asserted-by":"publisher","first-page":"1821","DOI":"10.1093\/neuonc\/noab150","article-title":"EANO guideline on the diagnosis and management of meningiomas","volume":"23","author":"Goldbrunner","year":"2021","journal-title":"Neuro Oncol."},{"key":"2026080714063678000_vdag186-B25","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1007\/s11060-022-04148-8","article-title":"Emerging systemic treatment options in meningioma","volume":"161","author":"Mair","year":"2023","journal-title":"J Neurooncol."},{"key":"2026080714063678000_vdag186-B26","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1002\/(SICI)1097-0215(19980529)76:5&lt;620::AID-IJC2&gt;3.0.CO","article-title":"Expression of somatostatin receptor subtypes in human brain tumors","volume":"76","author":"Dutour","year":"1998","journal-title":"Int J Cancer."},{"key":"2026080714063678000_vdag186-B27","doi-asserted-by":"publisher","first-page":"347","DOI":"10.2967\/jnumed.114.149120","article-title":"Increased 68Ga-DOTATATE uptake in PET imaging discriminates meningioma and tumor-free tissue","volume":"56","author":"Rachinger","year":"2015","journal-title":"J Nucl Med."},{"key":"2026080714063678000_vdag186-B28","doi-asserted-by":"publisher","first-page":"3390","DOI":"10.1007\/s00259-023-06315-z","article-title":"Next-generation PET\/CT imaging in meningioma-first clinical experiences using the novel SSTR-targeting peptide [(18)F]SiTATE","volume":"50","author":"Unterrainer","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2026080714063678000_vdag186-B29","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1093\/neuonc\/now001","article-title":"68Gallium-DOTATATE PET in meningioma: a reliable predictor of tumor growth rate?","volume":"18","author":"Sommerauer","year":"2016","journal-title":"Neuro Oncol."},{"key":"2026080714063678000_vdag186-B30","doi-asserted-by":"publisher","first-page":"1538","DOI":"10.1093\/neuonc\/now060","article-title":"Somatostatin receptor-targeted radionuclide therapy for progressive meningioma: benefit linked to 68Ga-DOTATATE\/-TOC uptake","volume":"18","author":"Seystahl","year":"2016","journal-title":"Neuro Oncol."},{"key":"2026080714063678000_vdag186-B31","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/j.mayocpiqo.2020.09.015","article-title":"Efficacy of (177)Lu-Dotatate therapy in the treatment of recurrent meningioma","volume":"5","author":"Zahid","year":"2021","journal-title":"Mayo Clin Proc Innov Qual Outcomes."},{"key":"2026080714063678000_vdag186-B32","doi-asserted-by":"publisher","first-page":"1279933","DOI":"10.3389\/fonc.2023.1279933","article-title":"A prognostic model for tumor recurrence and progression after meningioma surgery: preselection for further molecular work-up","volume":"13","author":"Padevit","year":"2023","journal-title":"Front Oncol."},{"key":"2026080714063678000_vdag186-B33","doi-asserted-by":"publisher","first-page":"936","DOI":"10.2967\/jnumed.108.061457","article-title":"Highly efficient in vivo agonist-induced internalization of sst2 receptors in somatostatin target tissues","volume":"50","author":"Waser","year":"2009","journal-title":"J Nucl Med."},{"key":"2026080714063678000_vdag186-B34","doi-asserted-by":"publisher","first-page":"5704","DOI":"10.3390\/cancers13225704","article-title":"Somatostatin receptors in human meningiomas-clinicopathological aspects","volume":"13","author":"Tollefsen","year":"2021","journal-title":"Cancers (Basel)"},{"key":"2026080714063678000_vdag186-B35","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1016\/j.jmb.2004.08.019","article-title":"Substantial energetic improvement with minimal structural perturbation in a high affinity mutant antibody","volume":"343","author":"Midelfort","year":"2004","journal-title":"J Mol Biol."},{"key":"2026080714063678000_vdag186-B36","doi-asserted-by":"publisher","first-page":"2537","DOI":"10.1110\/ps.051520605","article-title":"A mutation designed to alter crystal packing permits structural analysis of a tight-binding fluorescein-scFv complex","volume":"14","author":"Honegger","year":"2005","journal-title":"Protein Sci."},{"key":"2026080714063678000_vdag186-B37","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1182\/blood-2014-01-545020","article-title":"A highly compact epitope-based marker\/suicide gene for easier and safer T-cell therapy","volume":"124","author":"Philip","year":"2014","journal-title":"Blood."},{"key":"2026080714063678000_vdag186-B38","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1038\/nbt0396-309","article-title":"Human antibodies with sub-nanomolar affinities isolated from a large non-immunized phage display library","volume":"14","author":"Vaughan","year":"1996","journal-title":"Nat Biotechnol."},{"key":"2026080714063678000_vdag186-B39","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12102735","article-title":"Predicting the efficacy and safety of TACTICs (tumor angiogenesis-specific CAR-T cells impacting cancers) therapy for soft tissue sarcoma patients","volume":"12","author":"Fujiwara","year":"2020","journal-title":"Cancers (Basel)"},{"key":"2026080714063678000_vdag186-B40","doi-asserted-by":"publisher","first-page":"3875","DOI":"10.1182\/blood-2010-01-265041","article-title":"Adoptive transfer of syngeneic T cells transduced with a chimeric antigen receptor that recognizes murine CD19 can eradicate lymphoma and normal B cells","volume":"116","author":"Kochenderfer","year":"2010","journal-title":"Blood."},{"key":"2026080714063678000_vdag186-B41","doi-asserted-by":"publisher","first-page":"2412371","DOI":"10.1080\/2162402X.2024.2412371","article-title":"Peptide-guided adaptor-CAR T-cell therapy for the treatment of SSTR2-expressing neuroendocrine tumors","volume":"13","author":"Pellegrino","year":"2024","journal-title":"Oncoimmunology."},{"key":"2026080714063678000_vdag186-B42","doi-asserted-by":"publisher","first-page":"16436","DOI":"10.1073\/pnas.0607761103","article-title":"Radiolabeled somatostatin receptor antagonists are preferable to agonists for in vivo peptide receptor targeting of tumors","volume":"103","author":"Ginj","year":"2006","journal-title":"Proc Natl Acad Sci U S A."},{"key":"2026080714063678000_vdag186-B43","doi-asserted-by":"publisher","first-page":"2561","DOI":"10.1056\/NEJMoa1610497","article-title":"Regression of glioblastoma after chimeric antigen receptor T-Cell therapy","volume":"375","author":"Brown","year":"2016","journal-title":"N Engl J Med."},{"key":"2026080714063678000_vdag186-B44","doi-asserted-by":"publisher","first-page":"3149","DOI":"10.1158\/1078-0432.CCR-14-1421","article-title":"Phase I hepatic immunotherapy for metastases study of intra-arterial chimeric antigen receptor-modified T-cell therapy for CEA+ liver metastases","volume":"21","author":"Katz","year":"2015","journal-title":"Clin Cancer Res."},{"key":"2026080714063678000_vdag186-B45","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1038\/s41591-024-02928-5","article-title":"Locoregional delivery of IL-13Ralpha2-targeting CAR-T cells in recurrent high-grade glioma: a phase 1 trial","volume":"30","author":"Brown","year":"2024","journal-title":"Nat Med"},{"key":"2026080714063678000_vdag186-B46","doi-asserted-by":"publisher","first-page":"2778","DOI":"10.1038\/s41591-025-03745-0","article-title":"Intracerebroventricular bivalent CAR T cells targeting EGFR and IL-13R\u03b12 in recurrent glioblastoma: a phase 1 trial","volume":"31","author":"Bagley","year":"2025","journal-title":"Nat Med."},{"key":"2026080714063678000_vdag186-B47","doi-asserted-by":"publisher","first-page":"e2213222120","DOI":"10.1073\/pnas.2213222120","article-title":"Cytokine conjugation to enhance T cell therapy","volume":"120","author":"Liu","year":"2023","journal-title":"Proc Natl Acad Sci U S A."},{"key":"2026080714063678000_vdag186-B48","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1593\/neo.04595","article-title":"mTOR promotes survival and astrocytic characteristics induced by Pten\/AKT signaling in glioblastoma","volume":"7","author":"Hu","year":"2005","journal-title":"Neoplasia."},{"key":"2026080714063678000_vdag186-B49","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1101\/gad.349876.122","article-title":"Both YAP1-MAML2 and constitutively active YAP1 drive the formation of tumors that resemble NF2 mutant meningiomas in mice","volume":"36","author":"Szulzewsky","year":"2022","journal-title":"Genes Dev."},{"key":"2026080714063678000_vdag186-B50","doi-asserted-by":"publisher","first-page":"e12970","DOI":"10.1111\/bpa.12970","article-title":"Prognostic impact of genetic alterations and methylation classes in meningioma","volume":"32","author":"Berghoff","year":"2022","journal-title":"Brain Pathol."},{"key":"2026080714063678000_vdag186-B51","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1200\/JCO.21.02371","article-title":"Alliance A071401: phase II trial of focal adhesion kinase inhibition in meningiomas with somatic NF2 mutations","volume":"41","author":"Brastianos","year":"2023","journal-title":"J Clin Oncol."},{"key":"2026080714063678000_vdag186-B52","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","article-title":"Chimeric antigen receptor T cells for sustained remissions in leukemia","volume":"371","author":"Maude","year":"2014","journal-title":"N Engl J Med."},{"key":"2026080714063678000_vdag186-B53","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet."},{"key":"2026080714063678000_vdag186-B54","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1038\/s41586-022-04489-4","article-title":"GD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomas","volume":"603","author":"Majzner","year":"2022","journal-title":"Nature."},{"key":"2026080714063678000_vdag186-B55","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1038\/s41591-020-0827-2","article-title":"Locoregional delivery of CAR T cells to the cerebrospinal fluid for treatment of metastatic medulloblastoma and ependymoma","volume":"26","author":"Donovan","year":"2020","journal-title":"Nat Med."},{"key":"2026080714063678000_vdag186-B56","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1056\/NEJMoa2314390","article-title":"Intraventricular CARv3-TEAM-E T cells in recurrent glioblastoma","volume":"390","author":"Choi","year":"2024","journal-title":"N Engl J Med."},{"key":"2026080714063678000_vdag186-B57","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1158\/2159-8290.CD-23-0101","article-title":"Programming CAR T cell tumor recognition: tuned antigen sensing and logic gating","volume":"13","author":"Hamieh","year":"2023","journal-title":"Cancer Discov."},{"key":"2026080714063678000_vdag186-B58","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1158\/2159-8290.CD-17-1417","article-title":"Antitumor activity associated with prolonged persistence of adoptively transferred NY-ESO-1 (c259)T cells in synovial sarcoma","volume":"8","author":"D\u2019Angelo","year":"2018","journal-title":"Cancer Discov."},{"key":"2026080714063678000_vdag186-B59","doi-asserted-by":"publisher","first-page":"3549","DOI":"10.1038\/s41467-020-17175-8","article-title":"Tumor response and endogenous immune reactivity after administration of HER2 CAR T cells in a child with metastatic rhabdomyosarcoma","volume":"11","author":"Hegde","year":"2020","journal-title":"Nat Commun."},{"key":"2026080714063678000_vdag186-B60","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1038\/s41571-022-00704-3","article-title":"Overcoming on-target, off-tumour toxicity of CAR T cell therapy for solid tumours","volume":"20","author":"Flugel","year":"2023","journal-title":"Nat Rev Clin Oncol."},{"key":"2026080714063678000_vdag186-B61","doi-asserted-by":"publisher","first-page":"E10898","DOI":"10.1073\/pnas.1810060115","article-title":"Switchable control over in vivo CAR T expansion, B cell depletion, and induction of memory","volume":"115","author":"Viaud","year":"2018","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2026080714063678000_vdag186-B62","doi-asserted-by":"publisher","first-page":"3148","DOI":"10.1016\/j.cell.2023.06.002","article-title":"Vaccine-boosted CAR T crosstalk with host immunity to reject tumors with antigen heterogeneity","volume":"186","author":"Ma","year":"2023","journal-title":"Cell."},{"key":"2026080714063678000_vdag186-B63","doi-asserted-by":"publisher","first-page":"2248","DOI":"10.1158\/2159-8290.CD-20-1661","article-title":"IFNgamma is critical for CAR T cell-mediated myeloid activation and induction of endogenous immunity","volume":"11","author":"Alizadeh","year":"2021","journal-title":"Cancer Discov."},{"key":"2026080714063678000_vdag186-B64","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaa0984","article-title":"A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma","volume":"9","author":"O\u2019Rourke","year":"2017","journal-title":"Sci Transl Med"},{"key":"2026080714063678000_vdag186-B65","doi-asserted-by":"publisher","first-page":"1844","DOI":"10.1158\/0008-5472.CAN-11-3890","article-title":"A universal strategy for adoptive immunotherapy of cancer through use of a novel T-cell antigen receptor","volume":"72","author":"Urbanska","year":"2012","journal-title":"Cancer Res."},{"key":"2026080714063678000_vdag186-B66","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1038\/s41409-020-01134-4","article-title":"Taming the beast: CRS and ICANS after CAR T-cell therapy for ALL","volume":"56","author":"Sheth","year":"2021","journal-title":"Bone Marrow Transplant."},{"key":"2026080714063678000_vdag186-B67","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1038\/s41416-022-02061-5","article-title":"Dual [(68)Ga]DOTATATE and [(18)F]FDG PET\/CT in patients with metastatic gastroenteropancreatic neuroendocrine neoplasms: a multicentre validation of the NETPET score","volume":"128","author":"Chan","year":"2023","journal-title":"Br J Cancer."},{"key":"2026080714063678000_vdag186-B68","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1186\/s13014-021-01875-6","article-title":"68Ga-DOTATATE PET-CT as a tool for radiation planning and evaluating treatment responses in the clinical management of meningiomas","volume":"16","author":"Kowalski","year":"2021","journal-title":"Radiat Oncol."},{"key":"2026080714063678000_vdag186-B69","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1038\/s41591-024-02875-1","article-title":"Locoregional delivery of IL-13Ralpha2-targeting CAR-T cells in recurrent high-grade glioma: a phase 1 trial","volume":"30","author":"Brown","year":"2024","journal-title":"Nat Med."},{"key":"2026080714063678000_vdag186-B70","doi-asserted-by":"publisher","first-page":"2001","DOI":"10.1093\/neuonc\/noad108","article-title":"Chimeric antigen receptor T cell-based targeting of CD317 as a novel immunotherapeutic strategy against glioblastoma","volume":"25","author":"H\u00e4nsch","year":"2023","journal-title":"Neuro Oncol."},{"key":"2026080714063678000_vdag186-B71","doi-asserted-by":"publisher","first-page":"3104","DOI":"10.1093\/neuonc\/noaf155","article-title":"Mesothelin is a surface antigen present on human meningioma and can be effectively targeted by CAR T-cells","volume":"27","author":"Ramapriyan","year":"2025","journal-title":"Neuro Oncol"},{"key":"2026080714063678000_vdag186-B72","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1097\/MPA.0000000000000700","article-title":"Association between somatostatin receptor expression and clinical outcomes in neuroendocrine tumors","volume":"45","author":"Qian","year":"2016","journal-title":"Pancreas."},{"key":"2026080714063678000_vdag186-B73","first-page":"3997","article-title":"Expression of somatostatin type-2 and -4 receptor and correlation with histological type in breast cancer","volume":"34","author":"Frati","year":"2014","journal-title":"Anticancer Res."},{"key":"2026080714063678000_vdag186-B74","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1158\/1078-0432.CCR-20-3453","article-title":"177Lu-DOTA-EB-TATE, a radiolabeled analogue of somatostatin receptor type 2, for the imaging and treatment of thyroid cancer","volume":"27","author":"Thakur","year":"2021","journal-title":"Clin Cancer Res."},{"key":"2026080714063678000_vdag186-B75","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1038\/s41467-020-20308-8","article-title":"Somatostatin receptor 2 expression in nasopharyngeal cancer is induced by Epstein Barr virus infection: impact on prognosis, imaging and therapy","volume":"12","author":"Lechner","year":"2021","journal-title":"Nat Commun."},{"key":"2026080714063678000_vdag186-B76","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.3390\/pharmaceutics14071394","article-title":"Comprehensive assessment of somatostatin receptors in various neoplasms: a systematic review","volume":"14","author":"Priyadarshini","year":"2022","journal-title":"Pharmaceutics."},{"key":"2026080714063678000_vdag186-B77","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1093\/neuonc\/noab119","article-title":"Increase in contrast-enhancing volume of irradiated meningiomas reflects tumor progression and not pseudoprogression","volume":"23","author":"Wirsching","year":"2021","journal-title":"Neuro Oncol."},{"key":"2026080714063678000_vdag186-B78","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1097\/MNM.0000000000001198","article-title":"Nephrotoxicity\/renal failure after therapy with 90Yttrium- and 177Lutetium-radiolabeled somatostatin analogs in different types of neuroendocrine tumors: a systematic review","volume":"41","author":"Stolniceanu","year":"2020","journal-title":"Nucl Med Commun."},{"key":"2026080714063678000_vdag186-B79","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1038\/s41573-024-01051-x","article-title":"Immunogenicity risk assessment and mitigation for engineered antibody and protein therapeutics","volume":"23","author":"Carter","year":"2024","journal-title":"Nat Rev Drug Discov."}],"container-title":["Neuro-Oncology Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/noa\/advance-article-pdf\/doi\/10.1093\/noajnl\/vdag186\/69696802\/vdag186.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/noa\/article-pdf\/8\/1\/vdag186\/69696802\/vdag186.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/noa\/article-pdf\/8\/1\/vdag186\/69696802\/vdag186.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T18:06:49Z","timestamp":1786126009000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/noa\/article\/doi\/10.1093\/noajnl\/vdag186\/8739211"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":79,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1,12]]}},"URL":"https:\/\/doi.org\/10.1093\/noajnl\/vdag186","relation":{},"ISSN":["2632-2498"],"issn-type":[{"value":"2632-2498","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,1]]},"published":{"date-parts":[[2026,1]]},"article-number":"vdag186"}}